“I thoroughly enjoyed the  invaluable MMTC 2011 meeting which covered a broad spectrum of cutting-edge topics in molecular medicine with scientific, business and regulatory viewpoints. The quality of speakers was outstanding and while the conference was large enough in number to be impactful, it was also small in that there were many opportunities to make valuable contacts through the break-out sessions, panel discussions, early oncology partnering sessions and the pre-conference tutorials.”

Staff Scientist, Group Leader, DxTerity Diagnostics

“Clearly the place to learn, network and leave with a better plan to accelerate the success of molecular diagnostics.”
Vice President, Metamark Genetics

“Finding the thought leaders is always difficult. You have done a great job of getting some of the brightest and most productive at your meetings.”
Professor, Pathology; Associate Director Clinical Chemistry, The University of Virginia

“The meeting allowed me to hear from about half a dozen thought leaders on progress and plans for implementing NGS for molecular diagnosis. I avoided having to make several trips by being able to visit with colleagues at the event. I met several people for the first time who will be very helpful in advancing my work.”
Director, Center for Pediatric Genomic Medicine, Children's Mercy Hospital

“Participation in the Molecular Medicine Tri-conference was a unique experience for me relative to the spectrum of academic meetings that I usually attend.  While the conference addressed a broad spectrum of topics, it did so by incorporating groups and leaders beyond the scope of the usual suspects.  I was particularly interested in the industry and technology development thought leaders who helped to bridge the enormous chasm between what we do in the lab, and what we want to provide in terms of services to patients.  I wish more conferences could support this vital aspect of moving both the science and the technology into the hands of consumers.”
Assistant Professor, Clinical Research, Hematology/Oncology, University of North Carolina, Chapel Hill

“Molecular Medicine Tri-conference fosters healthy cross-pollination between academia and industry.”
Director, Molecular Pathology and Clinical Genomics, Creighton Medical Laboratories

“Superb content and outstanding networking opportunities”
Medical Director, Molecular Diagnostics, The Methodist Hospital

“Molecular Medicine Tri-conference: A success in bringing together academics, clinicians, and industry!”
Medical Countermeasures Group Leader, Senior Scientist, Physics, Lawrence Livermore National Laboratory

“Great access to experts from all facets of molecular medicine- time well spent.”
Director, Business Development, Catholic Health Initiatives (CHI) Center for Translational Research

“Interesting to see that everyone is struggling with the choice of analytic methods for regulatory submissions.”
Co-Director, Pediatric Transplantation, University of Pittsburgh

“An excellent mix of academic and industry viewpoints.  Excellent networking opportunities.”
Associate Investigator, Center for Cancer Research, National Cancer Institute, National Institutes of Health

“Overall a great meeting and I learnt lot from it. Platform to discuss the latest science and latest technologies.”
Assistant Professor, Department of Surgery, University of Minnesota

“Best venue for academia and industry to learn, interact and appraise the current and future impact of cutting edge technologies on clinical medicine.”
Chief, Hematopathology Service, Beth Israel Deaconess Medical Center; Director, Hematopathology Fellowship Site Director, HMS Molecular Genetic Pathology Fellowship; Assistant Professor of Pathology, Harvard Medical School

“The conference was just an incredible insight into the present state and forthcoming future of molecular medicine. By bringing together the very experts from the leading edge technologies of molecular medicine, you created an environment for cross-fertilization of ideas and technologies unmatched by any other conference in the world. Indeed, unlike many meetings organized by specialized professional societies narrowly focused on one topic, TRICON 2011 expanded horizons towards the new frontiers of molecular medicine. The most advanced areas of work from circulating tumor cells through regenerative medicine stem cell therapies to development of new drugs were presented during multiple sessions. Almost all speakers presented data and analyses of their findings at the molecular level setting the highest levels of professional standards. The presentations were followed by the vivid discussions with the speakers. As the participants were from clinics, academia, industry, and federal agencies. Interactions of all these professionals were extremely stimulating.”
Associate Professor of Genetics, Genomics, and Gene Therapy, Director of Biotechnology Program, Western University of Health Sciences

“I very much enjoyed the session and was quite impressed by the program of the conference!”
Direktor der Frauenklinik, Klinikum der Heinrich-Heine-Universität Düsseldorf

“The meeting provided detailed recent results and historical perspectives in presentations by the key contributors to the field.”
Manager, Biomedical Engineering, Palo Alto Research Center

“The meeting allowed me to hear about new technologies that could be applied clinically and gave me a lot of new ideas for future research projects and possible collaborations.”
Surgical Oncology Fellow, Department of Surgical Oncology, Fox Chase Cancer Center

“Knowledge discovery and new insights are an outcome of conversations among eclectic people from disparate disciplines. MMTC provides the perfect forum for creating these conversations and collaborations.”
Vice President, Health & Life Sciences, Point Cross Inc.

“The Molecular Medicine Tri-conference is one of the key conferences covering all aspects of molecular & translational medicine advances in a single high quality event, that everyone in industry and academia in life science should attend!”
Vice President, CSO, IO Informatics, Inc


“Tricon provided a great forum to explore the changes that pharma is undergoing and how the complexity of translational medicine needs to put focus on the patient and physician needs, not just technology development”
Managing Director, Strategic Medicine Inc.

“The CHI staff is extremely professional.  The content was great and the organization worked beautifully.
My session on cancer stem cells was very exciting.  The panel discussion involved lots of questions from the audience and the panelists were thoroughly engaged.”
Biotechnology Analyst, System Biosciences SBI

“Most conferences are highly specialized. The Tri-Conference presents a great opportunity to meet and talk with people outside my immediate area of expertise but nevertheless relevant to my research. I think the conference plays an important role in fostering integrative research.”
Professor, Biology, CSO, Ovarian Cancer Institute, Georgia Institute of Technology

“I really enjoyed the cutting-edge research presented. The tracks were relevant to each other. It was excellent to hear about the latest developments in several fields.”
Assistant Professor, Systems Biology, the University of Texas, M.D. Anderson Cancer Center

“The 2011 Molecular Medicine Tri-Conference was an excellent opportunity to hear about several important and emerging areas of drug discovery all in one meeting.  This ranged from numerous discussions on translational medicine and clinical progress to the state-of-the-art in the new fields of circulating tumor cells and cancer stem cells.  The quality of the speakers was outstanding, and the many opportunities to discuss current topics with other scientists, including short courses, workshops, and discussion sessions, made this a very productive conference.  I look forward to participating again next year.”
Director, Cancer Biology, MedImmune, Inc.

“I particularly enjoyed attending this conference on account of its special mixture of technologies and products that are very innovative but also near or in clinical development. It was really fascinating to learn about novel approaches and concepts that are close to or in the process of being tested in patients.
Chief Scientific Officer, Affimed Therapeutics AG

“It was a well run and organized conference and I enjoyed it. The venue was great and the session topics and presentations were outstanding.”
Scientist II, Cancer Biology, MedImmune, Inc.

“The conference was a great venue to learn about novel ADC technology and its clinical applications.  There was a great mix of basic science presentations and clinical trial updates.”
Product Development, Oncology, Genentech, Inc.

“The meeting was organized very well covering the most important topics with regard to cancer biologics. It was a nice meeting and I certainly very much enjoyed it. I hope to have an opportunity to give a speech next year.”
Principal Investigator, Division of Monoclonal Antibodies, OBP-CDER-FDA

“What I personally got from the conference was the opportunity to get a new perspective on areas that I was less familiar with, and to learn what the new research/new initiatives were in areas where I am more knowledgeable.”
Division Chair, Drug Delivery, Drug Research and Development, Professor Emeritus, Pharmacology and Oncology, University of Alberta

“The breakout round-table discussion on Wed evening was very good. It might be nice to have a second session on Thursday over lunch.”
Senior Vice President, Research & Translational Medicine, Seattle Genetics, Inc.

“I particularly enjoyed the whole series of presentations under "Developments with antibody drug conjugates" which took us through a case study (the Keynote presentation) and then dealt with 3 major aspects of antibody conjugates: the antibody itself, the linker and the toxin/drug. This session was very informative for me.”
Biotechnology Research Institute, National Research Council, Canada

“The scientific breadth of the Molecular Medicine Tri-conference provided a great opportunity to extend my knowledge both in areas of science of immediate interest and in new areas of science at the same time – well worth attending.”
Chief Scientist, Oncology Discovery, AstraZeneca

“I continually find the Molecular Medicine Tri Conference to be an excellent, broad conference that presents the latest work by the top scientists in the field.”
Co-Leader, Development Therapeutics program, Fox Chase Cancer Center

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

Premier Sponsors

Beckman Coulter Life Sciences 

Boston Healthcare



Charles River no tagline


Cofactor Genonics


Menarini Silicon Biosystems






View All Sponsors